<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693378</url>
  </required_header>
  <id_info>
    <org_study_id>PanFAM-1</org_study_id>
    <nct_id>NCT03693378</nct_id>
  </id_info>
  <brief_title>A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups</brief_title>
  <official_title>A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups.
      The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™
      PanCan-d test compared to standard-of-care imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PanFAM-1 is a prospective, multi-center, investigational study, designed to assess the
      performance of the IMMray™ PanCan-d test in early detection of pancreatic ductal
      adenocarcinoma (PDAC) in high-risk populations. Specifically, the IMMray PanCan-d test uses
      state of the art machine learning algorithms to condense the multiple fluorescence data
      points generated by the test to a simple yes/no result. Thus, a highly complex statistical
      model uses the multi-dimensional nature of the test to generate a score, which is called a
      decision value. The score is compared to the established cut-off value for the test to inform
      the operator whether the patient sample is positive or negative for PDAC. This study will
      validate and evaluate the performance of the IMMray PanCan-d test in comparison to standard
      of care imaging approaches that are currently used in PDAC disease surveillance. Subjects in
      this study will be recruited from several European and North American research sites that
      have a PDAC surveillance program or established protocol for monitoring individuals
      considered to be at a high-risk for developing pancreatic cancer. Any subject that shows
      disease progression while on-study will be removed from the study to receive standard of care
      per institutional guidelines. Overall, this study poses minimal risk to subjects. The
      PanFAM-1 study is an adaptive study design over two approximately 18 month intervals, which
      are separated by an interim analysis to evaluate diagnostic accuracy of the IMMray PanCan-d
      test. This study is an observational period in which blood collections from eligible subjects
      will be evaluated using the IMMray PanCan-d test. Subjects will undergo scheduled imaging
      assessment and clinical evaluation consistent with the resarch sites' PDAC surveillance
      program. Subject data derived from the IMMray PanCan-d test during this portion of the study
      will be delayed from time of initial blood collection until the samples are analyzed. The
      analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging
      assessments performed as part of standard of care PDAC surveillance. The study will only
      proceed to the interventional period if the interim analysis indicates that the diagnostic
      accuracy of the IMMray PanCan-d test is capable of detecting PDAC in high-risk subjects with
      the same or better ability as standard of care imaging. If at any time imaging assessments
      are considered positive for clinical disease then, regardless of IMMray PanCan-d test
      results, subjects will be managed according to institutional guidelines. All scheduled blood
      collections for purposes of this study will be halted and subjects will be removed from the
      study upon confirmation of PDAC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of IMMray™ PanCan-d test</measure>
    <time_frame>Approximately 18 months upon collection of approximately 2,000 subjects, or disease progression, whichever comes first</time_frame>
    <description>Demonstrate that the IMMray PanCan-d test is equal or better than the reference standard imaging procedures for early detection of PDAC in asymptomatic high risk individuals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the IMMray™ PanCan-d test performance</measure>
    <time_frame>Approximately 18 months upon collection of approximately 2,000 subjects, or disease progression, whichever comes first</time_frame>
    <description>Point Estimates and 95% confidence intervals</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Familial Pancreatic Cancer</condition>
  <condition>FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        High-risk patient population, enrolled in established PDAC screening programs
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent document

          2. Individuals with the following family phenotype and age:

               1. Two or more relatives with pancreatic adenocarcinomas (PDAC) on the same side of
                  the family, where two PDAC-affected individuals are first degree related (FDR) +
                  at least one PDAC-affected individual is a FDR of the Participant (≥50 years old
                  OR 10 years before onset in family)

               2. Two affected FDR with PDAC (≥50 years old OR 10 years before onset of an FDR)

               3. Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely
                  pathogenic + one FDR or secondary degree related (SDR) with PDAC (≥50 years old
                  OR 10 years before onset of an FDR and SDR)

               4. Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or
                  likely pathogenic mutation variants in: p16, CDKN2A (≥50 years old)

               5. Known mutation carrier for STK11 (Peutz Jeghers Syndrome) (≥35 years old)

               6. Lynch syndrome (HNPCC) with confirmed pathogenic or likely pathogenic variants
                  in: MLH1, MSH2, MSH6, PMS2, or EPCAM + one FDR or SDR with PDAC (≥50 years old OR
                  10 years before onset of an FDR or SDR)

               7. Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic
                  history of pancreatitis (≥40 years old)

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Ehrnström</last_name>
    <role>Study Director</role>
    <affiliation>Immunovia, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy Callahan, RN</last_name>
    <email>cindy.callahan@immunovia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Glantz</last_name>
    <email>susanne.glantz@immunovia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Gastroenterology and Hepatology</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Park, Dr</last_name>
      <email>wgpark@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Walter Park, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8327</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Farrell</last_name>
      <email>james.j.farrell@yale.edu</email>
    </contact>
    <investigator>
      <last_name>James Farrell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Kupfer, MD</last_name>
      <email>skupfer@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chung</last_name>
      <email>Chung.Daniel@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giles Whalen</last_name>
      <email>Giles.Whalen@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Giles Whalen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Simeone</last_name>
      <email>Diane.Simeone@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Diane Simeone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fay Kastrinos, MD</last_name>
      <email>fk18@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>aimee.lucas@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Aimee Lucas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Hampel, MS, LGC</last_name>
      <email>Heather.Hampel@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Hampel, MS, LGC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niko Millington</last_name>
      <email>millingt@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Brett Sheppard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryson Katona</last_name>
      <email>Bryson.Katona@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Bryson Katona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Brand</last_name>
      <email>brandre@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Randall Brand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanka Kanth, MD</last_name>
      <email>priyanka.kanth@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Priyanka Kanth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Zogopoulos</last_name>
      <email>George.zogopoulos@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>George Zogopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Carrato</last_name>
      <email>acarrato@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Alfredo Carrato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Herraiz</last_name>
      <email>mherraizb@unav.es</email>
    </contact>
    <investigator>
      <last_name>Teresa Herraiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Santiago De Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Enrique Dominguez-Munoz</last_name>
      <email>edominguezmunoz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Enrique Dominguez-Munoz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Persson</last_name>
      <email>Jan.Persson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Jan Persson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gasslander</last_name>
      <email>thomas.gasslander@liu.se</email>
    </contact>
    <investigator>
      <last_name>Thomas Gasslander</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urban Arnelo</last_name>
      <email>Urban.arnelo@ki.se</email>
    </contact>
    <investigator>
      <last_name>Urban Arnelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malin Sund, Prof</last_name>
      <email>malin.sund@umu.se</email>
    </contact>
    <investigator>
      <last_name>Malin Sund, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Collage London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Pereira, Prof.</last_name>
      <email>stephen.pereira@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Pereira, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol. 2018 Oct 1;36(28):2887-2894. doi: 10.1200/JCO.2017.77.6658. Epub 2018 Aug 14.</citation>
    <PMID>30106639</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-risk familial</keyword>
  <keyword>screening program</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Dysplastic Nevus Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

